Aspire is proud to announce we have received PMTA Acceptance letter from the FDA on March 18, 2021. We have reached a step closer to meeting FDA criteria for a full scientific review before moving onto the next step of the PMTA process.
The documentation includes a broad and exhaustive investigation with scientific evidence of the quality and safety of our electronic nicotine-delivery systems (ENDS).
This letter confirms that Aspire’s application has met the preliminary statutory and regulatory FDA requirements under section 910 of the Federal Food, Drug, and Cosmetic Act (the FD&C Act) (21 U.S.C. 387j).
Aspire looks forward to cooperating with FDA during the preliminary scientific review process and further demonstrating the safety and quality of our products.
Aspire believes in normal and logical regulations to protect the people against harmful tobacco products. We also believe that the ENDS industry should offer high-quality products that comply with health and marketing standards.
The Aspire Team